Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: Correlation with high IL-6 and low IL-2 blood concentrations

被引:0
作者
Lissoni, P [1 ]
Brivio, F [1 ]
Pittalis, S [1 ]
Rovelli, F [1 ]
Rescaldani, R [1 ]
Perego, MS [1 ]
Grassi, MG [1 ]
Barni, S [1 ]
Tancini, G [1 ]
Majorca, F [1 ]
Fumagalli, L [1 ]
机构
[1] OSPED SAN GERARDO,DIV RADIOTERAPIA ONCOL,I-20052 MONZA,ITALY
关键词
anticancer immunity; erythrosedimentation rate; interleukin-2; interleukin-6;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite its well documented unfavourable prognostic significance in several human diseases, including cancer, the cytokinic mechanisms responsible for an increased erythrosedimentation rate (ESR) still remain to be better analyzed and defined The recent possibility to measure cytokine concentrations in the blood of patients has allowed us to explore the possible relation between ESR values and endogenous cytokine secretions. This preliminary study was performed to evaluate the relationship between ESR values and serum levels of IL-2 and IL-6, which represent the most important cytokines responsible for the activation and the suppression, respectively, of host anticancer immune reaction. The study included 33 consecutive solid tumor patients, 22 of whom showed distant organ metastases. Abnormally high values of ESR were present in 21 patients, including 18/22 metastatic patients and 3/11 nonmetastatic patients. Patients with elevated values of ESR showed significantly higher mean levels of IL-6 and significantly lower mean concentrations of IL-2 with respect to those found in patients with normal ESR values. These results would show that cancer-related increase in ESR values is associated with low levels of IL-2 and high levels of IL-6. Since IL-2 plays an essential role in the anticancer immunity and IL-6 may suppress the antitumor immune defenses, the evidence of low levels of IL-2 and high values of IL-6 in cancer patients with increased ESR values would explain the unfavourable prognostic significance of high ESR values in human neoplasms.
引用
收藏
页码:60 / 62
页数:3
相关论文
共 9 条
[1]   CANCER, CYTOKINES, AND CYTOTOXIC-CELLS - INTERLEUKIN-2 IN THE IMMUNOTHERAPY OF HUMAN NEOPLASMS [J].
ATZPODIEN, J ;
KIRCHNER, H .
KLINISCHE WOCHENSCHRIFT, 1990, 68 (01) :1-11
[2]  
BEUTLER B, 1987, NEW ENGL J MED, V316, P379
[3]   THE BIOLOGY OF INTERLEUKIN-6 [J].
KISHIMOTO, T .
BLOOD, 1989, 74 (01) :1-10
[4]  
LISSONI P, 1991, ONCOLOGY, V48, P125
[5]   IN-VIVO TIME AND DOSE-DEPENDENCY OF INTERLEUKIN-6 SECRETION IN RESPONSE TO LOW-DOSE SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 [J].
MEFFERT, M ;
HANNINEN, EL ;
MENZEL, T ;
SCHOMBURG, A ;
DUENSING, S ;
DALLMANN, I ;
GROSSE, J ;
VOCKE, S ;
BUER, J ;
DECKERT, M ;
HILSE, R ;
KIRCHNER, H ;
POLIWODA, H ;
ATZPODIEN, J .
CANCER BIOTHERAPY, 1994, 9 (04) :307-316
[6]  
MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121
[7]   INTERLEUKIN-1 - BIOLOGY, PATHOPHYSIOLOGY, AND CLINICAL PROSPECTS [J].
PLATANIAS, LC ;
VOGELZANG, NJ .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (05) :621-629
[8]   SERUM INTERLEUKIN-6 AND C-REACTIVE PROTEIN-LEVELS CORRELATE WITH RESISTANCE TO IL-2 THERAPY AND POOR SURVIVAL IN MELANOMA PATIENTS [J].
TARTOUR, E ;
DORVAL, T ;
MOSSERI, V ;
DENEUX, L ;
MATHIOT, C ;
BRAILLY, H ;
MONTERO, F ;
JOYEUX, I ;
POUILLART, P ;
FRIDMAN, WH .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :911-913
[9]  
VANHAL PTW, 1994, J IMMUNOL, V153, P2718